Drug Profile
IONIS FB LRx
Alternative Names: RO-7434656; ASO Factor B; IONIS-FB-LRx; IONIS-FB-LRX; ISIS-696844; RG-6299Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Ionis Pharmaceuticals
- Developer Ionis Pharmaceuticals; Roche
- Class Antisense oligonucleotides; Eye disorder therapies
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III IgA nephropathy
- Phase II Age-related macular degeneration
Most Recent Events
- 21 Jun 2023 Roche plans to file regulatory filing for IgA nephropathy, in or after 2026 (Roche pipeline, June 2023)
- 21 Jun 2023 Roche plans to submit regulatory fillings in Age-related macular degeneration, in or after 2026 (Roche pipeline, June 2023)
- 17 May 2023 Phase-III clinical trials in IgA nephropathy (In adults, In the elderly) in USA (SC) (NCT05797610)